Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alz-Dementia Korea Co. is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active case is assigned to 1 distinct examiner and is situated within 1 distinct art unit. Such a focused portfolio profile indicates that the company's current patenting activity is concentrated on a specific technical advancement or a single application.
PRIEST, AARON A serves as the busiest examiner for the portfolio, managing 1 pending office action. This 1 busiest examiner pending case constitutes the entirety of the company's current workload under review. The involvement of 1 distinct art unit suggests that the subject matter is being evaluated within a specific regulatory and technical framework at the patent office. Because there is only 1 pending office action and 1 distinct examiner, the prosecution strategy is currently centered on a single point of contact. This data provides a clear view of the company's immediate priorities in the Biotechnology & Pharmaceuticals field. The alignment of the active file with a single examiner may streamline the negotiation process during prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRIEST, AARON A | 1 | 61.3% | +25.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682176 | microRNA BIOMARKER FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT OR ALZHEIMER TYPE DEMENTIA | PRIEST, AARON A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682176 | microRNA BIOMARKER FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT OR ALZHEIMER TYPE DEMENTIA | PRIEST, AARON A | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682176 | microRNA BIOMARKER FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT OR ALZHEIMER TYPE DEMENTIA | PRIEST, AARON A | 1681 | §101§102§112 | Non-Final OA | — | Pending | Feb 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial